NASDAQ$OTLK
Outlook Therapeutics Inc · Q2 2026 earnings
Q2 2026 earnings · · After market close · Investor relations
Briefing
Outlook Therapeutics Inc reported Q2 2026 results showing initial commercial revenue from LYTENAVA and a reduced net loss compared to the prior year.
For the three months ended March 31, 2026, Outlook Therapeutics generated net revenues of $127,439 from sales of LYTENAVA in Europe while reporting a net loss of $4.45 million. The company continued advancing regulatory discussions with the FDA regarding its BLA for ONS-5010/LYTENAVA and maintained a cash position of $7.75 million at quarter end. Operating expenses remained elevated due to commercial launch activities and ongoing development efforts.
- Net revenues reached $127,439 in the first full quarter of European commercial sales of LYTENAVA.
- Net loss narrowed significantly to $4.45 million from $46.36 million in the prior-year quarter, aided by gains on warrant liability revaluation.
- Cash and cash equivalents stood at $7.75 million with total assets of $21.89 million as of March 31, 2026.
- Common shares outstanding increased to 104,614,219 following equity issuances and note conversions during the quarter.
Headline financials
Revenue & EPS history
Outlook Therapeutics · Revenue · Quarterly
$127K
Forward guidance
Company continues to engage with FDA on regulatory pathway for ONS-5010 following third CRL and plans further European commercial expansion.
Tailwinds
- Marketing authorizations secured in EU and UK with ongoing launches in additional markets
- NORSE EIGHT data showed vision improvement and favorable safety profile
Headwinds
- FDA requires confirmatory efficacy evidence for U.S. approval
- Substantial doubt remains regarding ability to continue as going concern without additional financing
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2026
+5.1%
Avg return
Earnings day
+6.9%
Avg return
5 days after
-0.7%
Avg return
30 days after
61%
25 / 41 earnings
Positive
+48.5%
Q2 2019
Best reaction
-14.6%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.3% | -0.9% | — | |
| Q1 2026 | -13.9% | -15.7% | -31.4% | |
| Q4 2025 | -2.9% | -11.6% | -73.6% | |
| Q3 2025 | +14.1% | +23.5% | -51.2% | |
| Q2 2025 | +1.2% | +9.9% | -0.6% | |
| Q1 2025 | +1.6% | -7.9% | -14.7% | |
| Q4 2024 | +9.4% | +11.2% | +17.1% | |
| Q3 2024 | -0.9% | -7.6% | -16.5% | |
| Q2 2024 | -0.9% | +7.4% | +3.6% | |
| Q1 2024 | +21.2% | +13.0% | +3.0% | |
| Q4 2023 | +4.2% | +8.2% | -18.5% | |
| Q3 2023 | -3.1% | -16.9% | -85.3% | |
| Q2 2023 | +3.5% | +16.5% | +46.1% | |
| Q1 2023 | -3.3% | -7.5% | -15.8% | |
| Q4 2022 | +6.9% | +4.0% | +15.8% | |
| Q3 2022 | -3.4% | +5.9% | -4.2% | |
| Q2 2022 | +7.4% | +2.7% | -37.1% | |
| Q1 2022 | +3.7% | +8.1% | +36.3% | |
| Q4 2021 | -4.2% | -1.4% | -14.6% | |
| Q3 2021 | -14.6% | -16.2% | -1.6% | |
| Q2 2021 | +16.0% | +21.2% | +34.1% | |
| Q1 2021 | -0.4% | -4.0% | -9.5% | |
| Q4 2020 | +1.3% | -4.6% | -13.1% | |
| Q3 2020 | +5.2% | +14.2% | -54.5% | |
| Q2 2020 | +1.9% | -1.9% | +40.4% | |
| Q1 2020 | +0.0% | -1.1% | -35.1% | |
| Q4 2019 | -1.7% | -53.0% | -11.1% | |
| Q3 2019 | -4.2% | -8.9% | -17.8% | |
| Q2 2019 | +48.5% | +191.3% | +125.2% | |
| Q1 2019 | +28.2% | +28.2% | -5.8% | |
| Q4 2018 | +24.5% | +42.9% | +34.7% | |
| Q3 2018 | +1.2% | -8.8% | +0.0% | |
| Q2 2018 | +2.7% | +1.1% | -13.3% | |
| Q1 2018 | +4.3% | +3.5% | -19.0% | |
| Q4 2017 | +0.0% | -7.9% | -4.8% | |
| Q3 2017 | +0.5% | +3.0% | +77.8% | |
| Q2 2017 | -8.7% | -34.1% | -24.5% | |
| Q1 2017 | +10.6% | +2.1% | -1.2% | |
| Q4 2016 | +28.6% | +40.3% | +59.8% | |
| Q2 2016 | +28.6% | +40.3% | +59.8% | |
| Q3 2016 | -3.9% | -5.3% | -8.1% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro